BiotechTube

IPH5201 + durvalumab + standard chemotherapy

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer

Trial Timeline

Jun 23, 2023 → Sep 1, 2026

NCT ID
NCT05742607

About IPH5201 + durvalumab + standard chemotherapy

IPH5201 + durvalumab + standard chemotherapy is a phase 2 stage product being developed by Innate Pharma for Non Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05742607. Target conditions include Non Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05742607Phase 2Recruiting

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Pemetrexed + CarboplatinEli LillyPhase 3
77
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3NanobiotixPhase 1/2
36
PemetrexedEli LillyPre-clinical
23
pemetrexed + erlotinibEli LillyPhase 2
52
LY3295668 ErbumineEli LillyPhase 1
33
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
69
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
69
pemetrexed + cisplatinEli LillyPhase 2
52
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
52
CetuximabEli LillyPhase 1
33
pemetrexed + docetaxelEli LillyPhase 3
77
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
52
PemCarbo + Pem onlyEli LillyPhase 3
77
TNG456 + abemaciclibEli LillyPhase 1/2
41
pemetrexed + cisplatinEli LillyPhase 1/2
41

Other Products from Innate Pharma

IPH2101Phase 2
44
IPH4102Phase 2
44
IPH2101Phase 2
44
avdoralimabPhase 2
44
Lacutamab + Gemcitabine + OxaliplatinePhase 2
44